ChemicalBook >> CAS DataBase List >>Tofacitinib

Tofacitinib

CAS No.
477600-75-2
Chemical Name:
Tofacitinib
Synonyms
3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile;Tasocitinib;Tofacitinib base;Tofacitinib (CP-690550,Tasocitinib);Tofactinib;CS-344;CP 690550;Tofatinib;ofacitinib;Tofacitinib
CBNumber:
CB0970901
Molecular Formula:
C16H20N6O
Molecular Weight:
312.38
MDL Number:
MFCD11035919
MOL File:
477600-75-2.mol
MSDS File:
SDS
Last updated:2024-04-16 16:23:18

Tofacitinib Properties

Density 1.3
storage temp. -20°C
solubility Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 100 mg/ml).
form Pale powder.
pka 6.04±0.60(Predicted)
color Off-white
Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChI InChI=1/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/s3
InChIKey UJLAWZDWDVHWOW-BCFRMRSDNA-N
SMILES N([C@@H]1[C@@H](CCN(C(=O)CC#N)C1)C)(C1N=CN=C2NC=CC=12)C |&1:1,2,r|
CAS DataBase Reference 477600-75-2
FDA UNII 87LA6FU830
NCI Drug Dictionary tofacitinib
ATC code L04AA29

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS09
Signal word  Warning
Hazard statements  H410
Precautionary statements  P501-P273-P391
HS Code  29335990

Tofacitinib price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Usbiological C7905-90 Tofacitinib 477600-75-2 25mg $215 2021-12-16 Buy
Biosynth Carbosynth FT32555 Tofacitinib 477600-75-2 500mg $225 2021-12-16 Buy
Activate Scientific AS17628-A Tofacitinib 98% 477600-75-2 1g $250 2021-12-16 Buy
Biosynth Carbosynth FT32555 Tofacitinib 477600-75-2 1g $300 2021-12-16 Buy
ChemScene CS-0050 Tofacitinib 99.96% 477600-75-2 1g $330 2021-12-16 Buy
Product number Packaging Price Buy
C7905-90 25mg $215 Buy
FT32555 500mg $225 Buy
AS17628-A 1g $250 Buy
FT32555 1g $300 Buy
CS-0050 1g $330 Buy

Tofacitinib Chemical Properties,Uses,Production

Description

In November 2012, the US FDA approved tofacitinib (also referred to as CP-690550) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. Tofacitinib is the first small molecule kinase inhibitor approved for the treatment of RA. Tofacitinib is an inhibitor of the four subtypes of Janus kinase (JAK): JAK1, JAK2, JAK3, and Tyk2. The JAKs are intracellular, nonreceptor tyrosine kinases that play important roles in the signal transduction pathway of many cytokines (e.g., interleukins 2, 4, 7, 9, 15, and 21) and are involved in the propagation of inflammation in RA. Tofacitinib acts by inhibiting the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby suppressing the production of inflammatory mediators in joint tissue. At the enzyme level, tofacitinib inhibits JAKs 1, 2, 3, and Tyk2 with IC50s of 3.2, 4.1, 1.6, and 34 nM, respectively. At the cellular level, tofacitinib inhibits the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50s of 406, 56, and 1377 nM, respectively.

Chemical Properties

Light Pink to Pale Orange Solid

Originator

Pfizer (United States)

Uses

CP-690550 is a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis

Indications

The JAK family includes four isoforms, JAK1, JAK2, JAK3, and tyrosine kinase (TYK2). Ruxolitinib (Jakafi(R), Incyte Corp.) was the first approved JAK inhibitor, which inhibits both JAK1 and JAK2, used for the treatment of different types of myelofibrosis. Tofacitinib (Xeljanz(R), Pfizer) was approved by FDA as a JAK3-selective inhibitor for the treatment of rheumatoid arthritis and is one of the only two FDA-approved kinase inhibitors for non-oncological indications.

Definition

ChEBI: A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely ctive rheumatoid arthritis.

brand name

Xeljanz

Synthesis

Commercially available aminopyridine 171 was reacted with dimethyl dicarbonate in the presence of potassium t-butoxide to give the methyl carbamate 172 in 87% yield. Hydrogenation of this carbamate 172 in the presence of 20 wt% of 5% Rh/C (JM type C101023-5) in acetic acid followed by reductive amination with benzaldehyde and sodium triacetoxy borohydride furnished the cis-benzyl protected piperidine 173 in 73% yield. Reduction of the methyl carbamate within 173 with lithium aluminum hydride (LAH) in THF gave the corresponding methyl amino piperidine which was isolated as the dihydrochloride salt 174 in 87% yield. Enantiomeric resolution of the methyl amino piperidine was achieved by freebasing the di-hydrochloride salt 174 with sodium hydroxide and then conversion to the di-toluol-L-tartaric acid salt followed by crystallization to give 175 in 42% yield and 98.6% ee. The enantioenriched tartrate salt 175 was then directly reacted with dichloride 176 (obtained from reaction of commercial 7H-pyrrolo[2,3-d]pyrimidine-2,4-diol (178) with phosphorous oxychloride) in the presence of potassium carbonate in water to give the coupled product 177 in essentially quantitative yield. Hydrogenation of intermediate 177 with DeGussa?ˉs catalyst triggered concomitant debenzylation and chloride removal, and this was followed by installation of the cyanoacetate group and subsequent treatment with citric acid to provide tofacitinib citrate (XXVII) in 90% yield.

Synthesis_477600-75-2

References

1) Jiang et al. (2008), Examining the chirality, confirmation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitril (CP-690,550); J. Mol. Chem., 51 8012 2) Cutolo and Meroni (2013), Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis; J. Inflamm. Res., 6 129 3) Martina et al. (2016), Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro; Transplant. Proc., 48 3046 4) Moisan et al. (2015), White-to-brown metabolic conversion of human adipocytes by JAK inhibition; Nat. Cell Biol., 17 57 5) Dowty et al. (2014), Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis; J. Pharmacol. Exp. Ther., 348 165

Tofacitinib Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 459)Suppliers
Supplier Tel Email Country ProdList Advantage
Changsha Junyu Chemexpress.co., Ltd
+86-13723890100 info@csjyyy.cn China 134 58
Changzhou Rokechem Technology Co., Ltd.
18758118018 sales001@rokechem.com China 255 58
Senova Technology Co. Ltd.
+86-0755-86703119 +8618503098836 info@senovatech.com China 349 58
Wuhan Boyuan Import & Export Co., LTD
+8615175982296 Mike@whby-chem.com China 974 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578 sales@hbmojin.com China 12453 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652 info@fdachem.com China 7377 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 sales@capotchem.com China 29797 60
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886 info@dakenam.com China 15371 58
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 sales01@cooperate-pharm.com CHINA 1811 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21695 55

Related articles

  • Biological activity of PLX-4720
  • PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y....
  • Oct 11,2019

View Lastest Price from Tofacitinib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Tofacitinib pictures 2024-04-16 Tofacitinib
477600-75-2
US $5.00-0.10 / KG 1KG 99% g-kg-tons, free sample is available Henan Fengda Chemical Co., Ltd
Tofacitinib pictures 2024-01-08 Tofacitinib
477600-75-2
US $23.00-15.00 / kg 1kg 99.50% 20 tons Wuhan Boyuan Import & Export Co., LTD
Tofacitinib  pictures 2024-01-08 Tofacitinib
477600-75-2
US $36.00-20.00 / kg 1kg 99.50% 20 tons Wuhan Boyuan Import & Export Co., LTD
  • Tofacitinib pictures
  • Tofacitinib
    477600-75-2
  • US $5.00-0.10 / KG
  • 99%
  • Henan Fengda Chemical Co., Ltd
  • Tofacitinib pictures
  • Tofacitinib
    477600-75-2
  • US $23.00-15.00 / kg
  • 99.50%
  • Wuhan Boyuan Import & Export Co., LTD
  • Tofacitinib  pictures
  • Tofacitinib
    477600-75-2
  • US $36.00-20.00 / kg
  • 99.50%
  • Wuhan Boyuan Import & Export Co., LTD

Tofacitinib Spectrum

3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)-2-oxopiperidin-1-yl)propanenitrile Tropsch iMatinib CP 690550 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile Tofacitinib,CP-690550 Tofacitinib, >=98% 3-[4(R)-Methyl-3(R)-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]- 3-oxopropanenitrile (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-2-piperidinepropanenitrile 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile(CP-690550) CP 690550 3-Piperidinamine, 1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo(2,3-D)pyrimidin-4-yl-, (3R,4R)- CP-690550(Tasocitinib,CP690550) CP 690550(Tasocitinib) 3-((3R,4R)-4-Methyl-3-(Me... Tasocitinib (CP 690550) 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)- 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-, (3R,4R)- Tofacitinib CP-690550 Tofacitinib 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropa ofacitinib Tofacitinib USP/EP/BP CP-690550 DISCONTINUED Tofacitinib 13C D2 15N Tofacitinib 13C3Q: What is Tofacitinib 13C3 Q: What is the CAS Number of Tofacitinib 13C3 Q: What is the storage condition of Tofacitinib 13C3 Q: What are the applications of Tofacitinib 13C3 Tofacitinib D3Q: What is Tofacitinib D3 Q: What is the CAS Number of Tofacitinib D3 Tofaimpurity Tofacitinib citrate, ≥98% (HPLC) CP 690550 - Tasocitinib | Tofacitinib 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile, Tofacitinib 3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile CS-344 CP690550 (Tofacitinib, Tasocitinib was stopped use) Tofacitinib ?Tasocitinib TOFACITINIB;TASOCITINIB;CP-690550;CP690550 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Tasocitinib Tofacitinib (CP-690550,Tasocitinib) Tofactinib Tofacitinib base 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R)- Dapagliflozin Impurity 148 Tofatinib 477600-75-2 Inhibitors Inhibitor API 477600-75-2 LFQ